Literature DB >> 12439121

Utilization of cornstarch in glycogen storage disease type Ia.

Olaf A Bodamer1, Francois Feillet, Rebecca E Lane, Philip J Lee, Marjorie A Dixon, Dave Halliday, James V Leonard.   

Abstract

OBJECTIVE: Uncooked cornstarch (UCCS) is used widely for the treatment of patients with glycogen storage disease type I (GSD-I). Previous studies suggested that glucose absorption may be impaired in GSD-I. In order to measure utilization of UCCS in young adults with GSD-Ia and healthy controls, we used a C-breath test based on the natural enrichment of C in UCCS.
DESIGN: Open, not randomized, prospective interventional study.
METHODS: Following 1 g/kg UCCS, we studied eight subjects with GSD-Ia (7 males, 1 female; mean age 28.3 years, range 16-42 years) and 15 healthy controls (10 males, 5 females; mean age 23.5 years, range 19-36 years). Breath samples for analysis of CO enrichment were collected at baseline and at 30-min intervals for 6 h or until hypoglycaemia occurred. Indirect calorimetry was used to measure respiratory gas exchange. Intermediate metabolites, lipids and glucose were measured in plasma. Breath H concentrations were measured as an indicator of malabsorption.
RESULTS: Cumulative utilization over 6 h was significantly higher in controls (18.35 +/- 6.2% of total carbohydrate intake) than in subjects with GSD-Ia (11.5 +/- 4.7%) (P < 0.02). However, utilization of UCCS was virtually identical up to 2.5 h. Two subjects with GSD-Ia fulfilled the criteria for malabsorption.
CONCLUSIONS: Starch digestion and absorption are not impaired in GSD-Ia. However, overall utilization of UCCS appears to be lower in GSD-Ia, which is most likely secondary to perturbed intermediary metabolism. There are important implications for treatment of this disorder. Ways to improve the efficacy of UCCS in GSD-I are needed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12439121     DOI: 10.1097/00042737-200211000-00014

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  7 in total

Review 1.  Dietary dilemmas in the management of glycogen storage disease type I.

Authors:  Kaustuv Bhattacharya
Journal:  J Inherit Metab Dis       Date:  2011-04-14       Impact factor: 4.982

2.  Development of minimally invasive 13C-glucose breath test to examine different exogenous carbohydrate sources in patients with glycogen storage disease type Ia.

Authors:  Abrar Turki; Sylvia Stockler; Sandra Sirrs; Ramona Salvarinova; Gloria Ho; Jennifer Branov; Annie Rosen-Heath; Taryn Bosdet; Rajavel Elango
Journal:  Mol Genet Metab Rep       Date:  2022-05-11

Review 3.  Glycogen storage diseases: new perspectives.

Authors:  Hasan Ozen
Journal:  World J Gastroenterol       Date:  2007-05-14       Impact factor: 5.742

4.  A novel starch for the treatment of glycogen storage diseases.

Authors:  K Bhattacharya; R C Orton; X Qi; H Mundy; D W Morley; M P Champion; S Eaton; R F Tester; P J Lee
Journal:  J Inherit Metab Dis       Date:  2007-05-19       Impact factor: 4.982

5.  Immunocytochemical localization of glucose 6-phosphatase and cytosolic phosphoenolpyruvate carboxykinase in gluconeogenic tissues reveals unsuspected metabolic zonation.

Authors:  Fabienne Rajas; Hélène Jourdan-Pineau; Anne Stefanutti; Elham Abou Mrad; Patrick B Iynedjian; Gilles Mithieux
Journal:  Histochem Cell Biol       Date:  2007-01-09       Impact factor: 2.531

6.  A pilot longitudinal study of the use of waxy maize heat modified starch in the treatment of adults with glycogen storage disease type I: a randomized double-blind cross-over study.

Authors:  Kaustuv Bhattacharya; Helen Mundy; Maggie F Lilburn; Michael P Champion; David W Morley; François Maillot
Journal:  Orphanet J Rare Dis       Date:  2015-02-15       Impact factor: 4.123

Review 7.  Dynamic Methods for Childhood Hypoglycemia Phenotyping: A Narrative Review.

Authors:  Alessandro Rossi; Martijn G S Rutten; Theo H van Dijk; Barbara M Bakker; Dirk-Jan Reijngoud; Maaike H Oosterveer; Terry G J Derks
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-17       Impact factor: 6.055

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.